{"database": "press", "table": "releases", "rows": [["https://degette.house.gov/media-center/press-releases/degette-leads-bipartisan-exploration-of-insulin-pricing-alternatives", "DeGette Leads Bipartisan Exploration of Insulin Pricing Alternatives", "2017-11-09", "2017", "2017-11", "Democrat", "House", "CO", "Diana DeGette", "D000197", "degette.house.gov", null, null, "legacy", "Washington, DC \u2013 The co-chairs of the Congressional Diabetes Caucus, Rep. Diana DeGette (D-CO) and Rep. Tom Reed (R-NY), have released a bipartisan request for stakeholders to provide information about whether health plans can pay for insulin based on how well the particular drug product works for patients.\nDeGette and Reed have issued a Request for Information (RFI) into whether value-based contracting could be applied to insulin. Value-based contracting encompasses a number of different possible payment arrangements where reimbursement is tied to the achievement of certain pre-set goals.\u00a0 For example, these arrangements could reimburse for drugs based on patient outcomes or a drug\u2019s efficacy on different indications. They could also limit costs to a negotiated threshold or focus on a specific subset of patients. During their initial stakeholder meetings this summer, several groups argued that value-based contracts could hold promise for lowering cost burdens on patients who need insulin. This RFI is a follow-up to those conversations.\n\u201cWe\u2019re in the midst of a long-term inquiry into insulin costs and pricing that involves a variety of stakeholders from patient advocates to the major drug manufacturers. The goal is to explore all potential avenues that could make this life-saving medication more affordable for patients,\u201d DeGette said. \u201cStakeholders and experts are telling us that innovative value-based contracts could be one tool to provide relief for patients. But we don\u2019t know much about how these contracts are actually used in practice, and would like to learn more.\u201d\n\u201cI am committed to providing cost relief to diabetes patients,\u201d Reed said. \u201cSince the cost of insulin has skyrocketed over recent years, it has become a priority of the Diabetes Caucus to find answers to the insulin price problem. As co-chair, I am interested in finding how value-based contracts would potentially reduce the cost of insulin.\u201d\nStakeholders are asked in the RFI to address any of a number of questions, or to submit other information that they believe could be helpful. The questions include:\n\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How does your organization define \u201cvalue-based contracts\u201d?\u00a0\u00a0\u00a0\u00a0\n\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Please describe how value-based contracting might work in the context of insulin.\u00a0 You can provide examples of current contracts or hypothetical future contracts.\n\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 How common are value-based contracts for insulin?\n\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Please describe any regulatory or statutory barriers to value-based contracting for insulin.\n\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Please describe any operational or administrative barriers to value-based contracting for insulin.\n\u00b7\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 To what extent is value-based contracting for pharmaceuticals being tested in government health care programs?\n\u00a0\nStakeholders are asked to provide their input by December 15, 2017 to Insulin.Inquiry@mail.house.gov.", 1, "2026-03-30T12:14:52Z", "2026-03-30T12:14:52Z"]], "columns": ["url", "title", "date", "year", "month", "party", "chamber", "state", "member_name", "bioguide_id", "domain", "scraper", "source", "date_source", "text", "has_text", "collected_at", "updated_at"], "primary_keys": ["url"], "primary_key_values": ["https://degette.house.gov/media-center/press-releases/degette-leads-bipartisan-exploration-of-insulin-pricing-alternatives"], "units": {}, "query_ms": 1.592471031472087, "source": "dwillis/congress-press", "source_url": "https://github.com/dwillis/congress-press", "license": "MIT", "license_url": "https://github.com/dwillis/congress-press/blob/main/LICENSE"}